<?xml version="1.0" encoding="UTF-8"?>
<ref id="B57-antibiotics-10-00092">
 <label>57.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Roberts</surname>
    <given-names>J.L.</given-names>
   </name>
   <name>
    <surname>Tavallai</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Nourbakhsh</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Fidanza</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Cruz-Luna</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Siembida</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Plamondon</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Cycon</surname>
    <given-names>K.A.</given-names>
   </name>
   <name>
    <surname>Doern</surname>
    <given-names>C.D.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>GRP78/Dna K is a target for Nexavar/Stivarga/Votrient in the treatment of human malignancies, viral infections and bacterial diseases</article-title>
  <source>J. Cell. Physiol.</source>
  <year>2015</year>
  <volume>230</volume>
  <fpage>2552</fpage>
  <lpage>2578</lpage>
  <pub-id pub-id-type="doi">10.1002/jcp.25014</pub-id>
  <pub-id pub-id-type="pmid">25858032</pub-id>
 </element-citation>
</ref>
